Ocera Therapeutics Inc (NASDAQ:OCRX) reported financial results for the quarter ended June 30, 2017. “We’ve enjoyed a busy quarter preparing to meet with …
Ocera Therapeutics Inc (NASDAQ:OCRX) announced the dosing of the first patients in Part Two of a Phase1/Phase 2a clinical trial of oral OCR-002 …
Ocera Therapeutics, Inc. (NASDAQ:OCRX) reported financial results for the quarter ended March 31, 2017 and provided updates on its clinical development programs of …
Ocera Therapeutics Inc (NASDAQ:OCRX) shareholders are enjoying a surprise rally in the stock today, after the drug maker announced that its clinical candidate OCR-002 prevented progression of …
H.C.
Ocera Therapeutics Inc (NASDAQ:OCRX) announced updates to its clinical development programs and reported financial results for the quarter and year ended December 31, …
Ocera Therapeutics Inc (NASDAQ:OCRX) and Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are soaring up, up, and away into the biotech-verse stratosphere today, and Aegis and …
Ocera Therapeutics, Inc. (NASDAQ:OCRX) investors should be smiling from ear to ear today after the drug maker disclosed that it will report additional encouraging …
Ocera Therapeutics Inc (NASDAQ:OCRX) disclosed last week that its Phase 2b clinical trial, STOP-HE, assessing lead product candidate OCR-002 (ornithine phenylacetate) in hospitalized patients …
Pulmatrix Inc (NASDAQ:PULM) shares are trading sharply down by 26% after the company announced that it had signed a definitive agreement with several …
